Current and historical daily PE Ratio for Malaysian Genomics Resource Centre Bhd (
) from 2010 to Jun 23 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Malaysian Genomics Resource Centre Bhd stock (XKLS:0155) PE ratio as of Jun 23 2024 is 0.
More Details
Malaysian Genomics Resource Centre Bhd (XKLS:0155) PE Ratio (TTM) Chart
Malaysian Genomics Resource Centre Bhd (XKLS:0155) PE Ratio (TTM) Historical Data
View and export this data going back to 2010. Start your Free Trial
Total 1280
- 1
- 2
- 3
- 4
- 5
- 6
- 15
Malaysian Genomics Resource Centre Bhd PE Ratio (TTM) Historical Data | |||
---|---|---|---|
Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
2024-06-23 | At Loss | 2024-04-16 | At Loss |
2024-06-21 | At Loss | 2024-04-15 | At Loss |
2024-06-20 | At Loss | 2024-04-12 | At Loss |
2024-06-19 | At Loss | 2024-04-09 | At Loss |
2024-06-18 | At Loss | 2024-04-08 | At Loss |
2024-06-14 | At Loss | 2024-04-05 | At Loss |
2024-06-13 | At Loss | 2024-04-04 | At Loss |
2024-06-12 | At Loss | 2024-04-03 | At Loss |
2024-06-11 | At Loss | 2024-04-02 | At Loss |
2024-06-10 | At Loss | 2024-04-01 | At Loss |
2024-06-07 | At Loss | 2024-03-29 | At Loss |
2024-06-06 | At Loss | 2024-03-27 | At Loss |
2024-06-05 | At Loss | 2024-03-26 | At Loss |
2024-06-04 | At Loss | 2024-03-25 | At Loss |
2024-05-31 | At Loss | 2024-03-22 | At Loss |
2024-05-30 | At Loss | 2024-03-21 | At Loss |
2024-05-29 | At Loss | 2024-03-20 | At Loss |
2024-05-28 | At Loss | 2024-03-19 | At Loss |
2024-05-27 | At Loss | 2024-03-18 | At Loss |
2024-05-24 | At Loss | 2024-03-15 | At Loss |
2024-05-23 | At Loss | 2024-03-14 | At Loss |
2024-05-21 | At Loss | 2024-03-13 | At Loss |
2024-05-20 | At Loss | 2024-03-12 | At Loss |
2024-05-17 | At Loss | 2024-03-11 | At Loss |
2024-05-16 | At Loss | 2024-03-08 | At Loss |
2024-05-15 | At Loss | 2024-03-07 | At Loss |
2024-05-14 | At Loss | 2024-03-06 | At Loss |
2024-05-13 | At Loss | 2024-03-05 | At Loss |
2024-05-10 | At Loss | 2024-03-04 | At Loss |
2024-05-09 | At Loss | 2024-03-01 | At Loss |
2024-05-08 | At Loss | 2024-02-29 | At Loss |
2024-05-07 | At Loss | 2024-02-28 | At Loss |
2024-05-06 | At Loss | 2024-02-27 | At Loss |
2024-05-03 | At Loss | 2024-02-26 | At Loss |
2024-05-02 | At Loss | 2024-02-23 | At Loss |
2024-04-30 | At Loss | 2024-02-22 | At Loss |
2024-04-29 | At Loss | 2024-02-21 | At Loss |
2024-04-26 | At Loss | 2024-02-20 | At Loss |
2024-04-25 | At Loss | 2024-02-19 | At Loss |
2024-04-24 | At Loss | 2024-02-16 | At Loss |
2024-04-23 | At Loss | 2024-02-15 | At Loss |
2024-04-22 | At Loss | 2024-02-14 | At Loss |
2024-04-19 | At Loss | 2024-02-13 | At Loss |
2024-04-18 | At Loss | 2024-02-12 | At Loss |
2024-04-17 | At Loss | 2024-02-09 | At Loss |
Malaysian Genomics Resource Centre Bhd (XKLS:0155) PE Ratio (TTM) Comparison
Company | Market Cap(Mil) | PE Ratio (TTM) |
---|
Business Description
Business Description
Malaysian Genomics Resource Centre Bhd
ISIN : MYQ0155OO000
Compare
Compare
Traded in other countries / regions
0155.Malaysia IPO Date
2010-10-05Description
Malaysian Genomics Resource Centre Bhd is a Malaysia-based company. The company's principal activities include enabling personalized and precision medicine through genetics, genomics, immunotherapy, and biopharmaceutical services, as well as investment holding. It offers genome sequencing and analysis (GSA) services, and genetic screening services (GSS). GSA services involve the sequencing and analysis of the DNA of humans, animals, plants, and microbes for biological information. The company provides GSS services through its own range of genetic screening tests under the brand Dtect which screens human DNA for genetic markers related to diseases and health conditions. It is also engaged in Research, development, and distribution of biopharmaceutical products and services.